Business Wire

Mitchell Lewis Joins Berkshire Hathaway HomeServices as Managing Director, EMEA

Del

Berkshire Hathaway HomeServices announced today that Mitchell Lewis will represent the real estate brokerage network as managing director, EMEA. Lewis will oversee franchise development and operations in key markets throughout Europe, the Middle East and Africa.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160929005411/en/

Mitch Lewis to lead Berkshire Hathaway HomeServices' network expansion in Europe (Photo: Business Wi ...

Mitch Lewis to lead Berkshire Hathaway HomeServices' network expansion in Europe (Photo: Business Wire)

Lewis brings vast international franchise sales and operations experience to his position, first at Cendant Corporation where he managed the global expansion and deal negotiations for Century 21, Coldwell Banker, Coldwell Banker Commercial and ERA. For the next decade at Realogy Corporation, he grew the global presence and enhanced the processes and systems for the same brokerage networks as well as Sotheby’s International Realty.

Most recently, Lewis served as the managing director of Asia Pacific for Christie’s International Real Estate, where he established the network’s operational presence and helped lead the brand’s global development. He also founded Munich-based Counterparts Advisory LLC to consult for consumer brands seeking franchise expansion and operational guidance around the world.

“Mitch Lewis is exactly the right professional to help us expand Berkshire Hathaway HomeServices,” said Peter Turtzo, SVP of International Operations. “He is an authority on international franchising having generated success at every turn. His extensive experience and professional acumen are true assets; he will indeed help us take our network global, far beyond its current presence in the United States.”

Lewis responded: “I am honored by the opportunity to assist Berkshire Hathaway HomeServices in its global expansion. The Berkshire Hathaway name is respected around the world, which gives Berkshire Hathaway HomeServices an advantage. I’m eager to explore target markets and work with franchisee candidates to see how the brand can help them grow and enhance profitability of their brokerage businesses.”

Berkshire Hathaway HomeServices announced international expansion plans in May with the simultaneous launch of a powerful, new property search platform on its website, www.berkshirehathawayhs.com. Global shoppers of U.S. real estate may translate the site in 10 languages, and their property searches yield all listings in any city serviced by a Berkshire Hathaway HomeServices franchisee. The network also initiated a listing syndication program that broadcasts its U.S. franchisees’ listings to real estate websites worldwide.

“These resources open gateways to the world for Berkshire Hathaway HomeServices’ U.S. affiliates long before a global franchise sales effort begins,” said Lewis. “This demonstrates careful planning and foresight by the brand to do things right the first time. In fact, Berkshire Hathaway HomeServices has exhibited extreme levels of due diligence, prudence and patience in its international expansion strategy.”

Lewis said his initial target markets will include major financial hubs along with destination and feeder markets throughout the EMEA region that exhibit stability in the property sector and where Berkshire Hathaway’s corporate name recognition runs high.

Berkshire Hathaway HomeServices CEO Gino Blefari welcomed Lewis in his new role. “Mitch is a globally astute executive who knows international franchise development and operations from all angles, and further understands the diligence we need to uphold the integrity of our brand name as we affiliate with leading real estate brokerages abroad,” he said. “He’s also an accomplished consultant who helped shape our global strategy and can guide franchisees to maximize their growth potential. We’re proud and confident knowing Mitch will be helping to expand our brokerage network.”

Lewis resides in Munich with his wife and two sons.

About Berkshire Hathaway HomeServices and HSF Affiliates LLC

Berkshire Hathaway HomeServices, based in Irvine, CA, is a real estate brokerage network built for a new era in residential real estate. The network, among the few organizations entrusted to use the world-renowned Berkshire Hathaway name, brings to the real estate market a definitive mark of trust, integrity, stability and longevity. Visit www.berkshirehathawayhs.com.

Irvine, CA-based HSF Affiliates LLC operates Berkshire Hathaway HomeServices, Prudential Real Estate and Real Living Real Estate franchise networks. The company is a joint venture of which HomeServices of America, Inc., the nation’s second-largest, full-service residential brokerage firm, is a majority owner. HomeServices of America is an affiliate of world-renowned Berkshire Hathaway Inc.

Prudential, the Prudential logo and the Rock symbol are service marks of Prudential Financial, Inc. and its related entities, and are used under license with no other affiliation with Prudential.

Contact information

Berkshire Hathaway HomeServices
Kevin Ostler
949-794-7980
kevinostler@hsfranchise.com
or
Alyssa Camacho
212-642-7732
alyssa.camacho@edelman.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom